Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01113008
Other study ID # PI-0327/2008
Secondary ID
Status Completed
Phase N/A
First received April 26, 2010
Last updated January 11, 2015
Start date February 2009
Est. completion date May 2012

Study information

Verified date January 2015
Source Hospital Universitario Virgen de la Victoria
Contact n/a
Is FDA regulated No
Health authority Spain: Ethics Committee
Study type Interventional

Clinical Trial Summary

The aim of this study is to evaluate the phenomenon of remote ischemic post-conditioning in humans. The minor myocardial damage associated with percutaneous revascularization procedures may be attenuated by producing controlled ischemia in the arms immediately after carrying out these procedures (remote ischemic post-conditioning). The justification and design of this clinical trial has been reported: Cardiology. 2011;119(3):164-9.


Description:

Percutaneous coronary intervention (PCI) has taken on an important role in the treatment of ischemic heart disease in recent years. However, the beneficial effects of revascularization are partly shadowed by post-reperfusion injury, which accounts for up to half the size of the reperfused myocardial infarct. Several drugs and procedures exist that might protect against this phenomenon. One of the most controversial of these strategies, which has shown promising results in experimental animal models, is remote ischemic post-conditioning. This involves inducing ischemia at a site remote from the heart after an ischemic coronary lesion to reduce the resulting myocardial infarct size.

The myocardial damage produced by ischemia-reperfusion associated with PCI is a known short- and long-term prognostic factor, and is associated with a greater risk of death, myocardial infarction and revascularization during the follow-up.

Our aim is to assess the phenomenon of remote ischemic post-conditioning in patients undergoing PCI, in whom the acute insult on the myocardium is determined by the angioplasty itself. Additionally, we aim to evaluate this phenomenon in a subgroup of diabetic patients, among whom the effectiveness of protective measures against post-reperfusion damage is more questioned.

We have designed a randomized, single-blinded interventional study involving 320 patients (40% diabetics) who are to undergo elective PCI. At the end of the angioplasty procedure, the patients assigned to remote ischemic post-conditioning will undergo three 5-minute cycles of ischemia using a blood-pressure cuff at 200 mmHg, placed on the non-dominant arm, interrupted twice for 5 minutes with the cuff deflated. In the control group the procedure will be limited to placing a deflated blood-pressure cuff (pressure: 0 mmHg) for 25 minutes.

The infarct size will be analyzed from an enzyme curve of troponin I and CK-MB values 0, 8, 16 and 24 hours after the procedure (primary endpoint). Measurements will also be taken of pH and lactate in the baseline sample (0 hours) and at 8 hours, and ultrasensitive C-reactive protein at 0 and 24 hours as a contrasted marker of inflammation in ischemic heart disease.

The follow-up, planned for one year, will seek to determine clinically interesting variables (secondary endpoint), such as readmission due to acute coronary syndrome, heart failure or major arrhythmic events and overall and cardiovascular mortality.


Recruitment information / eligibility

Status Completed
Enrollment 266
Est. completion date May 2012
Est. primary completion date February 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Patients undergoing PCI due to stable angina

2. Patients undergoing PCI due to unstable angina

3. Patients undergoing PCI due NON Q acute myocardial infarction with normal troponin at inclusion moment (less than 1 ng/ml)

Exclusion Criteria:

1. Acute myocardial infarction during the previous two weeks

2. Chronic renal failure with baseline creatinine above 3 mg/dL

4. Collateral circulation of the revascularized artery (Rantrop >0) 5. Prior treatment with glibenclamide. 6. Inability to receive follow-up, blood test or lack of informed consent.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)


Related Conditions & MeSH terms


Intervention

Procedure:
Remote ischemic postconditioning
Patients assigned to remote ischemic postconditioning will undergo three 5-minute cycles of ischemia using a blood-pressure cuff at 200 mmHg, placed on the non-dominant arm, interrupted twice for 5 minutes with the cuff deflated
Control group
In the control group the procedure will be limited to placing a deflated blood-pressure cuff (pressure: 0 mmHg) for 25 minutes.

Locations

Country Name City State
Spain Hospital Clínico Universitario Virgen de la Victoria Málaga

Sponsors (3)

Lead Sponsor Collaborator
Hospital Universitario Virgen de la Victoria FUNDACIÓN IMABIS, Red Temática de Investigación Cooperativa en Enfermedades Cardiovasculares

Country where clinical trial is conducted

Spain, 

References & Publications (11)

Ali ZA, Callaghan CJ, Lim E, Ali AA, Nouraei SA, Akthar AM, Boyle JR, Varty K, Kharbanda RK, Dutka DP, Gaunt ME. Remote ischemic preconditioning reduces myocardial and renal injury after elective abdominal aortic aneurysm repair: a randomized controlled trial. Circulation. 2007 Sep 11;116(11 Suppl):I98-105. — View Citation

Andreka G, Vertesaljai M, Szantho G, Font G, Piroth Z, Fontos G, Juhasz ED, Szekely L, Szelid Z, Turner MS, Ashrafian H, Frenneaux MP, Andreka P. Remote ischaemic postconditioning protects the heart during acute myocardial infarction in pigs. Heart. 2007 Jun;93(6):749-52. Epub 2007 Apr 20. — View Citation

Gritsopoulos G, Iliodromitis EK, Zoga A, Farmakis D, Demerouti E, Papalois A, Paraskevaidis IA, Kremastinos DT. Remote postconditioning is more potent than classic postconditioning in reducing the infarct size in anesthetized rabbits. Cardiovasc Drugs Ther. 2009 Jun;23(3):193-8. doi: 10.1007/s10557-009-6168-5. — View Citation

Hausenloy DJ, Mwamure PK, Venugopal V, Harris J, Barnard M, Grundy E, Ashley E, Vichare S, Di Salvo C, Kolvekar S, Hayward M, Keogh B, MacAllister RJ, Yellon DM. Effect of remote ischaemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: a randomised controlled trial. Lancet. 2007 Aug 18;370(9587):575-9. — View Citation

Hoole SP, Heck PM, Sharples L, Khan SN, Duehmke R, Densem CG, Clarke SC, Shapiro LM, Schofield PM, O'Sullivan M, Dutka DP. Cardiac Remote Ischemic Preconditioning in Coronary Stenting (CRISP Stent) Study: a prospective, randomized control trial. Circulation. 2009 Feb 17;119(6):820-7. doi: 10.1161/CIRCULATIONAHA.108.809723. Epub 2009 Feb 2. — View Citation

Iliodromitis EK, Kyrzopoulos S, Paraskevaidis IA, Kolocassides KG, Adamopoulos S, Karavolias G, Kremastinos DT. Increased C reactive protein and cardiac enzyme levels after coronary stent implantation. Is there protection by remote ischaemic preconditioning? Heart. 2006 Dec;92(12):1821-6. Epub 2006 Jul 19. — View Citation

JENNINGS RB, SOMMERS HM, SMYTH GA, FLACK HA, LINN H. Myocardial necrosis induced by temporary occlusion of a coronary artery in the dog. Arch Pathol. 1960 Jul;70:68-78. — View Citation

Jiménez-Navarro M, Gómez-Doblas JJ, Hernández García JM, Alonso-Briales J, García Alcántara A, Gómez G, Rodriguez-Bailón I, de Teresa E. Does angina pectoris the week before protect against first acute myocardial infarction in patients with diabetes mellitus? Am J Cardiol. 2002 Jul 15;90(2):160-2. — View Citation

Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986 Nov;74(5):1124-36. — View Citation

Staat P, Rioufol G, Piot C, Cottin Y, Cung TT, L'Huillier I, Aupetit JF, Bonnefoy E, Finet G, André-Fouët X, Ovize M. Postconditioning the human heart. Circulation. 2005 Oct 4;112(14):2143-8. Epub 2005 Sep 26. — View Citation

Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007 Sep 13;357(11):1121-35. Review. — View Citation

* Note: There are 11 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum Increase of Troponin at 24 Hours 24 hours No
Secondary Readmission Due to Acute Coronary Syndrome 12 month No
Secondary Cardiovascular Mortality 12 month No
See also
  Status Clinical Trial Phase
Recruiting NCT00989508 - Myocardial Protection With Perhexiline in Left Ventricular Hypertrophy Phase 2/Phase 3
Not yet recruiting NCT04570514 - Optimized Cardioprotection Therapy in Obese Subjects With AMI
Active, not recruiting NCT01857414 - Effect of RIC on Clinical Outcomes in STEMI Patients Undergoing pPCI N/A
Completed NCT02342522 - Effect of Remote Ischaemic Conditioning on Clinical Outcomes in STEMI Patients Undergoing PPCI (CONDI2/ERIC-PPCI) N/A
Active, not recruiting NCT05462730 - Pulse Glucocorticoid Therapy in Patients With ST-Segment Elevation Myocardial Infarction Phase 2
Completed NCT04397939 - Myocardial Injury and Major Adverse Outcomes in Patients With COVID-19
Withdrawn NCT02098629 - Concomitant Milrinone and Esmolol Treatment in Patients With Acute Myocardial Infarction Phase 1/Phase 2
Completed NCT00586820 - Role of Endothelin in Microvascular Dysfunction Following PCI for NSTEMI Phase 2
Completed NCT02390674 - Ciclosporin to Reduce Reperfusion Injury in Primary PCI Phase 2
Completed NCT00865722 - Remote Postconditioning in Patients With Acute Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention (PCI) Phase 2/Phase 3
Recruiting NCT01307371 - Cell Therapy in Diabetic Patients With ST-Segment Elevation Myocardial Infarction(STEMI) Phase 1
Completed NCT01379261 - Efficacy of Endovascular Catheter Cooling Combined With Cold Saline for the Treatment of Acute Myocardial Infarction Phase 2/Phase 3
Completed NCT00881686 - Myocardial Protection With Adenosine Preconditioning Phase 1/Phase 2
Completed NCT00484575 - Inhaled Sevoflurane Compared to Intravenous Sedation Post Coronary Artery Bypass Grafting Phase 1/Phase 2
Recruiting NCT03995732 - Efficacy and Safety Evaluation of PC-SOD for Injection in Reducing Myocardial Reperfusion Injury Phase 2
Recruiting NCT05775380 - The Role of Pioglitazone in Vascular Transcriptional Remodeling Phase 4
Completed NCT06450912 - Wall Strain Index Ratio as a Biomarker for Mechanical Complication of Hemorrhagic Myocardial Infarction
Completed NCT05354648 - Effects of Hypoxic-hyperoxic Preconditioning in Cardio-surgical Patients N/A
Completed NCT01601795 - Sevoflurane and Isoflurane - During Cardiopulmonary Bypass With the MECC System (Minimized Extracorporeal Circuit) Phase 4
Completed NCT01354808 - ACCEL-LOADING-ACS Study Phase 4